This bill directs the Department of Health and Human Services to create two federal tools to expand access to pre‑exposure prophylaxis (PrEP). One is a grant program to establish or support local PrEP programs; the other reimburses providers who deliver PrEP-related services to uninsured people and provides an access card to patients.
The measure targets gaps in access—rural areas, uninsured people, and demographic groups with high HIV incidence—by funding clinic costs, medications, testing, outreach, and supportive services. For policy and compliance teams, the bill creates new federal funding flows, reporting obligations, and provider registration and reimbursement mechanics that intersect with existing programs (Medicaid, Ryan White, FQHC operations).
At a Glance
What It Does
Creates a CDC-administered grant program for entities to start or expand PrEP programs and an HRSA-administered reimbursement program that pays program-registered providers for PrEP drugs and related services provided to uninsured individuals and issues a 'PrEP Pass' for no‑cost access.
Who It Affects
States, local governments, Indian Tribal governments, federally qualified health centers, rural health clinics, community-based organizations, hospital- and university-based clinics, and health care providers who care for uninsured or high‑risk populations.
Why It Matters
The bill channels dedicated federal dollars and a centralized reimbursement mechanism to lower financial and administrative barriers to PrEP. That combination is designed to increase uptake in underserved communities, produce disaggregated outcome data, and create new compliance and billing workflows for providers and grant recipients.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
Within one year of enactment, the Secretary of HHS (acting through the CDC in coordination with HRSA) must stand up a competitive grant program that funds entities to create or support PrEP programs. Grants are awarded through an application process and the Secretary must publish eligible expenses; the statute lists many permitted uses (clinic/lab fees, office and telehealth visits, medication, STD testing, adherence counseling, peer navigation, transportation, mental health, outreach and training for prescribers, and similar items).
The Secretary must prioritize applicants that serve communities with disproportionately high HIV incidence (explicitly including rural and uninsured populations) or that propose innovative delivery models such as vending machines, pop‑up clinics, and peer‑led interventions.
Each grant is capped at $10 million and grantees must generally provide a 10 percent match to the grant award, though the Secretary can waive that match for certain safety‑net providers (FQHCs, rural clinics, community‑based organizations, hospital‑ and university‑based clinics). The statute requires that services or items furnished through a funded PrEP program cannot be charged to the individual receiving them.
The Secretary must publish the list of eligible expenses and will have discretion to interpret “other similar items or services.”The bill authorizes $400 million annually for fiscal years 2027–2031 to carry out the grant program and related activities, and it requires the Secretary to report to Congress and post online for five consecutive years (starting one year after enactment) disaggregated data by race, gender identity, age, and geography, plus an evaluation of changes in PrEP prevalence and disparities. The statutory definitions catalog eligible entities (States, local governments, tribal governments, FQHCs, rural health clinics, community‑based organizations, hospital‑ and university‑based clinics) and define PrEP medication broadly as any FDA‑approved prevention drug.Separately, the bill obliges HHS (through HRSA) to set up a reimbursement program for providers who furnish specified HIV prevention items and services to uninsured individuals.
Program-registered providers submit claims to HHS and receive payment amounts set by the Secretary; payments for clinical diagnostic lab tests are tied to the payment rates established under section 1834A of the Social Security Act. The statute also mandates development and distribution of a “PrEP Pass” (card or other technology) that uninsured patients can present to access covered items and services at no cost; participating providers must agree not to hold the uninsured patient liable for those costs.
The Secretary must set and review payment rates at least every two years.
The Five Things You Need to Know
Grants: Each PrEP grant cannot exceed $10 million and must be used for eligible PrEP program expenses the Secretary publishes.
Authorization: The bill authorizes $400 million per year for fiscal years 2027 through 2031 to implement the Act.
PrEP Pass: The statute requires HHS to develop and distribute a ‘PrEP Pass’ (card or other technology) to ensure uninsured individuals access covered prevention items and services at no cost.
Matching: Grantees must generally provide a 10% match of the grant amount, but the Secretary may waive this requirement for FQHCs, rural health clinics, community‑based organizations, hospital‑based clinics, and university‑based clinics.
Lab reimbursement tie: Payments for clinical diagnostic laboratory tests under the reimbursement program must equal the payment amount determined under Medicare’s section 1834A rates.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Identifies the Act as the 'PrEP Assistance Program Act.' This is purely titular but signals the statute's focus on assistance rather than regulatory mandates.
Establishes the PrEP grant program, applications, and preference criteria
Requires HHS (via CDC, in collaboration with HRSA) to create a grants program within one year of enactment. Eligible applicants must submit applications specifying proposed uses. The Secretary must give preference to entities that serve communities with disproportionate HIV incidence—including rural and uninsured populations—and to applicants proposing innovative delivery models (vending machines, pop‑ups, peer‑led interventions), which creates an explicit policy steer toward both equity and experimentation.
Grant size, permitted uses, cost‑free services to recipients, and matching
Caps individual grants at $10 million and requires grantees to spend award funds on establishing or supporting PrEP programs. The statute includes a non‑exhaustive list of eligible expenses (medication, clinic/lab fees, telehealth, STD testing per CDC guidance, adherence counseling, peer navigation, transportation, mental health, outreach and prescriber education). It bars programs funded under the section from charging individuals for services or items received, and it imposes a 10% matching requirement on grantees with a discretionary waiver for certain safety‑net providers—an important design choice that preserves access for underresourced community providers while expecting cost‑sharing from better‑resourced grantees.
Reporting, authorization of appropriations, and statutory definitions
Requires annual public reports to Congress for five years (starting one year after enactment) containing disaggregated data by race, gender identity, age, and geography and an evaluation of reductions in PrEP disparities and prevalence. Authorizes $400 million per fiscal year for 2027–2031 to carry out the Act. Provides precise statutory definitions for 'eligible entity,' 'PrEP program,' 'PrEP medication,' and 'Indian Tribal government,' which shape program eligibility and administrative scope.
Reimbursement program for providers and the 'PrEP Pass'
Directs HHS (through HRSA) to establish a program where program‑registered providers submit claims for specified HIV prevention drugs and associated diagnostic services furnished to uninsured individuals. The Secretary must set payment amounts (with biennial review) and bind providers by agreement not to bill uninsured patients for items paid under the program. Clinical diagnostic lab tests are reimbursed at the Medicare-equivalent rates under section 1834A. The statute also requires HHS to develop and distribute a 'PrEP Pass' to uninsured individuals so they can access covered items and services at no cost, creating program logistics for enrollment, provider registration, and claims processing.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Uninsured individuals at risk of HIV infection — receive no‑cost access to PrEP medication, required laboratory testing, and supportive services through funded programs and the PrEP Pass.
- High‑risk and underserved communities (including rural populations and demographic groups with high HIV incidence) — targeted grant preference and outreach funding aim to increase service presence and culturally tailored interventions where gaps exist.
- Federally qualified health centers, rural health clinics, community‑based organizations, hospital‑ and university‑based clinics — gain a new federal funding stream to cover clinic costs, staff, outreach, and ancillary services tied to PrEP delivery.
- Peer navigators and community health workers — statute explicitly funds peer navigation, outreach, and adherence supports, likely increasing those roles and associated funding opportunities.
- Public health agencies and federal programs — will receive disaggregated outcome data to better target prevention efforts and evaluate reductions in disparities.
Who Bears the Cost
- Federal government / HHS budget — authorization of $400M annually creates a substantial appropriations pressure and places administrative obligations on CDC and HRSA to implement and oversee grants and reimbursements.
- Grant recipients (where matching applies) — most grantees must provide a 10% match, which could be cash or in‑kind and may strain smaller organizations that do not qualify for a waiver.
- Program‑registered providers — must register with the reimbursement program, accept program payment terms, and agree not to bill uninsured patients for covered items, which changes billing workflows and cash‑flow timing.
- HHS agencies (CDC and HRSA) and oversight offices — face implementation complexity: application review, monitoring allowable uses, fraud prevention for PrEP Passes, and compiling disaggregated reports.
- State programs and existing safety‑net funding streams (ADAP, Ryan White, Medicaid) — may see changed demand patterns and potential administrative overlap as federal grants and reimbursements interact with those programs.
Key Issues
The Core Tension
The central dilemma is between rapid, targeted expansion of no‑cost PrEP access for uninsured and high‑risk populations (which requires sizable federal funding, new administrative systems, and program mandates) and the desire to avoid creating fragmented, duplicative funding streams and short‑lived pilots; the bill increases access but shifts responsibility for coordination, technical implementation, and financial sustainability to agencies and grantees without prescribing full solutions.
Implementation raises several open questions. First, the bill erects new federal payment and grant flows that will overlap with existing state and federal programs (Medicaid coverage of PrEP, Ryan White HIV/AIDS Program, AIDS Drug Assistance Programs).
The statute does not specify how grantees or HRSA will coordinate benefits or prevent double‑billing between sources, nor does it set explicit priorities among funding streams. That gap will require durable interagency and state coordination guidance to avoid duplication or gaps in coverage.
Second, operational details matter for impact. The PrEP Pass centralizes patient access for the uninsured, but the bill leaves technological and anti‑fraud safeguards to HHS rulemaking and agency practice.
Payment adequacy is another risk: tying clinical lab payments to Medicare section 1834A fixes one benchmark, but the Secretary sets other rates and must review them biennially; if rates lag market costs, private providers may not participate. Finally, the program is authorized only through FY2031, raising sustainability questions: short‑term federal infusions can increase access quickly, but without longer‑term financing or coverage pathways, gains may not be durable.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.